| Dr David Louis Semenoff, MD | |
|
109 Bee St, Charleston, SC 29401-5703 | |
| (843) 577-5011 | |
| Not Available |
| Full Name | Dr David Louis Semenoff |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 109 Bee St, Charleston, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407877210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 053874 (Georgia) | Secondary |
| 207T00000X | Neurological Surgery | 151452 (New York) | Primary |
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629008537 PECOS PAC ID: 1759293111 Enrollment ID: O20031125000386 |
News Archive
Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).
Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.
A study released today by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health has identified the most feasible and impactful solutions for Nigeria's immunization program that could offer the best hope yet for scaling up vaccine access to the nation's most rural areas and taking aim at the country's precipitous number of child deaths.
› Verified 5 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548290455 PECOS PAC ID: 1759293111 Enrollment ID: O20040309001433 |
News Archive
Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).
Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.
A study released today by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health has identified the most feasible and impactful solutions for Nigeria's immunization program that could offer the best hope yet for scaling up vaccine access to the nation's most rural areas and taking aim at the country's precipitous number of child deaths.
› Verified 5 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1366872244 PECOS PAC ID: 1759293111 Enrollment ID: O20150618001757 |
News Archive
Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).
Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.
A study released today by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health has identified the most feasible and impactful solutions for Nigeria's immunization program that could offer the best hope yet for scaling up vaccine access to the nation's most rural areas and taking aim at the country's precipitous number of child deaths.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Louis Semenoff, MD 109 Bee St, Charleston, SC 29401-5703 Ph: (843) 577-5011 | Dr David Louis Semenoff, MD 109 Bee St, Charleston, SC 29401-5703 Ph: (843) 577-5011 |
News Archive
Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).
Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.
A study released today by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health has identified the most feasible and impactful solutions for Nigeria's immunization program that could offer the best hope yet for scaling up vaccine access to the nation's most rural areas and taking aim at the country's precipitous number of child deaths.
› Verified 5 days ago
Dr. Matthew T Neal, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414 Phone: 843-723-8823 | |
Steven Steuer Glazier, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. John D Steichen, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414 Phone: 843-723-8823 Fax: 843-606-8059 | |
Ricardo Alfonso Domingo Cabreja, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 843-792-2424 | |
Clayton Lee Haldeman, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414 Phone: 843-723-8823 | |
Dr. Sunil J Patel, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Stephen Robert Lowe, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 169 Ashley Ave, Room 202 Main Hospital Msc 333, Charleston, SC 29425 Phone: 843-792-1414 Fax: 843-792-9295 |